About Virupaksha Organics IPO
IPO Overview
Virupaksha Organics IPO is a 100% book-built offering, comprising a fresh issue worth up to ₹740 crore, with a face value of ₹10 per share. The company filed its DRHP with SEBI on September 29, 2025.
The price band and official dates of listing and subscription will be announced by the company later, but the shares are intended to be listed on the BSE and the NSE platforms. The book-running lead managers (BRLMs) of this issue are Axis Capital Ltd. and SBI Capital Markets Ltd., while the registrar to the issue is Kfin Technologies Ltd.
Company Background
Virupaksha Organics Ltd., incorporated in 1997 in Hyderabad, began as a modest chemical manufacturer. Over the last 28 years, they have undergone a profound transformation and become a research-oriented organisation composed of professionals from various fields dedicated to the application of pharmaceutical science.
The main goal is to create high-quality active pharmaceutical ingredients (APIs) and their intermediates, which are essential for the healthcare industry. From their roots in Hyderabad, they expand all over India, building deep and strong relationships with the global pharmaceutical giants who trust Virupaksha Organic for the essential building blocks of their medicine.
Operations & Product Range
The core operations of Virupaksha Organics Ltd. involve the manufacturing of APIs across various therapeutic segments, which include anti-histamine, anti-fungal and anti-diabetic treatments, among others. The company serves organic facilities and meets global health needs by providing raw pharmaceutical materials that eventually reach patients as finished dosage forms. By serving a diverse range of customers, ranging from the large domestic pharmaceutical firms to the international healthcare companies. Their business model relies on technical expertise in organic chemistry and the ability to manufacture complex molecules at scale.
Facilities & Capacity
Virupaksha Organics Ltd. operates 6 manufacturing facilities located in Telangana and Karnataka, with an aggregate of 223 reactors and a total reactor volume of 988 KL, as of FY25. These facilities are engaged with versatile reactor systems that must be capable of handling a wide range of chemical reactions. With this upcoming IPO, the company plans to establish a new manufacturing unit in Andhra Pradesh, which is intended to significantly boost the company's output and help meet the rising global demand for its products.
Brands & Market Presence
Virupaksha Organics Ltd. maintains several quality certifications required to operate in highly regulated markets, which makes its market presence remarkable. The company's revenue from outside India contributed 17.49%, 26.14%, and 32.92% of total revenue from operations for FY2025, FY2024, and FY2023, respectively. The main focus of the Virupaksha brand is on delivering high-quality products while maintaining its rigid standards and meeting the highest global standards, ensuring the safety and welfare of the people and the planet.
Revenue Streams & Business Model
Virupaksha Organics Ltd.'s revenue generation is from the sale of APIs and pharmaceutical intermediaries; their earnings are geographically diversified, with a near-even split between Indian sales and international exports. This model provides stability and access to high-margin opportunities in regulated foreign markets. For FY25, this company has maintained its growing revenue from operations Y-O-Y, as in FY25 it is recorded at ₹8,117.90 million and profit after tax (PAT) grew at ₹787.14 million in 2025.
Management & Shareholding
Promoters & Shareholding
The promoters of Virupaksha Organics Ltd. include Chandra Mouliswar Reddy Gangavaram, Balasubba Reddy Mamilla and several other members of the Gangavaram and Mamilla families. In the company, they collectively bring extensive experience in chemical engineering and pharmaceutical management. Before the IPO of the company, the promoters held a heavy stake in the equity of the company, but after the IPO, the promoters' holding will be reduced to the new public shareholders.
Board & Key Management
The board & key management of Virupaksha Organics Ltd. are led by Chandra Mouliswar Reddy Gangavaram (Managing Director). The leadership team is made up of the executive directors with technical backgrounds and independent directors who provide oversight in areas such as audit, risk management and corporate governance.
Virupaksha Organics IPO Details
| Detail | Description |
|---|---|
| IPO Date | - |
| Listing Date | - |
| Face Value | ₹ 10 per Equity Share |
| Issue Price Band | - |
| Lot Size | - |
| Sale Type | Fresh Issue only |
| Total Issue Size | [.] shares (agg. up to ₹ 740 Cr) |
| Fresh Issue(Ex Market Maker) | Up to ₹ 740.00 Cr (aggregating up to 7,400.00 million)* |
| Offer for Sale | Not applicable |
| Issue Type | 100 % Book Built Issue |
| Listing At | BSE and NSE |
| Share Holding Pre Issue | 6,15,31,937 shares |
| Share Holding Post Issue | - |
Virupaksha Organics IPO Financial Information
Latest Revenue
816.52
₹ Crore
Profit After Tax
78.71
₹ Crore
Net Worth
456.62
₹ Crore
Total Borrowing
282.23
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 952.48 | 816.52 | 78.71 | 456.62 | 415.87 | 282.23 | |||
| 31 Mar 2024 | 696.69 | 769.45 | 73.68 | 275.31 | 238.44 | 264.35 | |||
| 31 Mar 2023 | 601.76 | 650.65 | 43.09 | 209.71 | 197.96 | 240.85 | |||
| Amount in ₹ Crore | |||||||||
Virupaksha Organics Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 21.51% |
| ROCE | 19.12% |
| Debt/Equity | 0.58x |
| RoNW | 17.25% |
| PAT Margin | 9.70% |
| EBITDA Margin | 17.77% |
| Price to Book Value | - |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 13.7 | [.] |
| P/E (x) | [.] | [.] |
IPO Objectives
The company intended to use the Virupaksha Organics IPO for strategic purposes:
- • Capital Expenditure is planned for setting up the new manufacturing facility at Atchutapuram, Andhra Pradesh
- • Repayment of debt
- • General corporate purposes
Conclusion
Virupaksha Organics IPO is an opportunity for investors to invest in a growing company that has maintained a strong track record in the pharmaceutical ingredients space, driven by its multi-facility operations and significant export contribution. This IPO mainly aims to support the new manufacturing facility, debt repayment and general corporate purposes. Virupaksha Organics is concentrating on utilising its R&D capabilities to increase its share of the global API market.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
R&D-Driven Product Portfolio with 54 products (23 APIs, 31 intermediates) serving 550+ clients across 100+ countries through 6 manufacturing facilities.
Strong Financial Performance achieving ₹811 Cr revenue and ₹78 Cr PAT in FY25, supported by ₹360 Cr capex for strategic capacity expansion.
| Sr.no | Description | Date | File |
|---|---|---|---|
| 1 | Filed with SEBI/Exchange | 29/09/2025 | - |
| 2 | SEBI/Exchange approval received | - | - |
Virupaksha Organics IPO Timeline
| IPO Open Date | - |
| IPO Close Date | - |
| Tentative Allotment | - |
| Initiation of Refunds | - |
| Credit of Shares to Demat | - |
| Tentative Listing Date | - |
| Cut-off time for UPI mandate confirmation | - |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | — | ~₹14,000 - ₹15,000 |
| Individual investors (Retail) (Max) | 13-14 | — | Up to ₹2,00,000 |
| S-HNI (Min) | 14-15 | — | Over ₹2,00,000 |
| S-HNI (Max) | 66-70 | — | Up to ₹10,00,000 |
| B-HNI (Min) | 71+ | — | Over ₹10,00,000 |


